View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
May 10, 2017

OncoSec and Merck to begin Phase II combination trial to treat metastatic melanoma

US-based biotechnology company OncoSec has entered a clinical trial collaboration and supply agreement with Merck to begin the Phase II PISCES clinical trial of ImmunoPulse IL-12 and keytruda combination for the treatment of patients with metastatic melanoma.

US-based biotechnology company OncoSec has entered a clinical trial collaboration and supply agreement with Merck to begin the Phase II PISCES clinical trial of ImmunoPulse IL-12 and keytruda combination for the treatment of patients with metastatic melanoma.

Keytruda (pembrolizumab) is Merck’s anti-PD-1 therapy, while OncoSec’s ImmunoPulse is an investigational technology developed to increase the local delivery and uptake of DNA-based immune-targeting agents such as IL-12.

Under the agreement, OncoSec will sponsor and fund the study, while Merck will provide keytruda.

The trial will assess the safety and efficacy of the combination in stage III/IV metastatic melanoma patients who are experiencing disease progression after prior treatment with an anti-PD-1 therapy.

OncoSec president and chief executive officer Punit Dhillon said: “This collaboration is supported by our recent clinical data demonstrating the potential ability of ImmunoPulse IL-12 to rescue patients who do not initially respond to anti-PD-1 therapy in melanoma.

“In addition to our recent fast-track designation for this population, OncoSec is uniquely positioned to meaningfully impact clinical outcomes for patients who do not currently have any other options.

"In addition to our recent fast-track designation for this population, OncoSec is uniquely positioned to meaningfully impact clinical outcomes for patients who do not currently have any other options."

“By working with innovative immuno-oncology leaders, this alliance underpins OncoSec's strategy to combine our ImmunoPulse IL-12 programme with checkpoint inhibitor therapies to advance the care of patients."

ImmunoPulse IL-12 has reportedly shown anti-tumour activity and a favourable safety profile in Phase I and II trials for the treatment of different solid tumours.

OncoSec is further assessing ImmunoPulse IL-12 in patients with triple-negative breast cancer.

The firm is also working towards developing new immune-targeting agents for use with their ImmunoPulse.


Image: Histopathologic image of malignant melanoma. Photo: courtesy of KGH via Wikipedia.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena